Company Summary - BTG PLC (LSE:BGC)
163.80p
0.80p
(0.49%)
FTSE 250 Pharmaceuticals & BiotechnologyMarket cap: £421.873m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Development and commercialisation of life science technologies
| Financials - Interim (5/11/2009) | ||
|---|---|---|
| Turnover | £m | 47.9 |
| Pre-tax Profit | £m | 2.4 |
| EPS | p | 1.56 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Dr. John Brown | Chairman |
| Dr. Pamela Makin | Chief Executive |
| Rolf Soderstrom | Finance Director & Company Sec |
Products Brands & Subsidiaries
Products & Brands
ABIO-0801; ATV; Acadra; B-amyloid inhibitors; BGC20-0134; BGC20-1531; CB7630; Campath; CytoFab; Juvidex; Modafinil combination...
Subsidiaries
Provensis Ltd; BTG International Ltd; BTG Investment (Holdings) Ltd; BTG International (Holdings) Ltd...
Broker Sentiment (4 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| NOTIFICATION OF MAJOR INTER... | 18/11/2009 |
| Half Yearly Report | 05/11/2009 |
| Total Voting Rights | 02/11/2009 |